Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

Cited In for PubMed (Select 19641000)

1.

Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.

Eshaghi A, Shalhoub S, Rosenfeld P, Li A, Higgins RR, Stogios PJ, Savchenko A, Bastien N, Li Y, Rotstein C, Gubbay JB.

Antimicrob Agents Chemother. 2014 Dec;58(12):7188-97. doi: 10.1128/AAC.03667-14. Epub 2014 Sep 22.

2.

Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.

Samson M, Abed Y, Desrochers FM, Hamilton S, Luttick A, Tucker SP, Pryor MJ, Boivin G.

Antimicrob Agents Chemother. 2014 Sep;58(9):5220-8. doi: 10.1128/AAC.03313-14. Epub 2014 Jun 23.

3.

A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade.

Oh DY, Hurt AC.

Scientifica (Cairo). 2014;2014:430629. doi: 10.1155/2014/430629. Epub 2014 Apr 2. Review.

4.

Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro.

Denisova OV, Söderholm S, Virtanen S, Von Schantz C, Bychkov D, Vashchinkina E, Desloovere J, Tynell J, Ikonen N, Theisen LL, Nyman TA, Matikainen S, Kallioniemi O, Julkunen I, Muller CP, Saelens X, Verkhusha VV, Kainov DE.

Antimicrob Agents Chemother. 2014 Jul;58(7):3689-96. doi: 10.1128/AAC.02798-13. Epub 2014 Apr 21.

5.

Pretreatment of mice with oligonucleotide prop5 protects them from influenza virus infections.

Li K, Zhou Z, Wang YO, Liu J, Zhao HB, Yang J, Wang SQ.

Viruses. 2014 Feb 6;6(2):573-81. doi: 10.3390/v6020573.

6.

Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013.

Sleeman K, Mishin VP, Guo Z, Garten RJ, Balish A, Fry AM, Villanueva J, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2014;58(4):2045-51. doi: 10.1128/AAC.02556-13. Epub 2014 Jan 21.

7.

Comparison of mutation patterns in full-genome A/H3N2 influenza sequences obtained directly from clinical samples and the same samples after a single MDCK passage.

Lee HK, Tang JW, Kong DH, Loh TP, Chiang DK, Lam TT, Koay ES.

PLoS One. 2013 Nov 1;8(11):e79252. doi: 10.1371/journal.pone.0079252. eCollection 2013.

8.

Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.

Tamura D, Nguyen HT, Sleeman K, Levine M, Mishin VP, Yang H, Guo Z, Okomo-Adhiambo M, Xu X, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2013 Dec;57(12):6141-6. doi: 10.1128/AAC.01364-13. Epub 2013 Sep 30.

9.

Molecular evolution of the hemagglutinin and neuraminidase genes of pandemic (H1N1) 2009 influenza viruses in Sendai, Japan, during 2009-2011.

Khandaker I, Suzuki A, Kamigaki T, Tohma K, Odagiri T, Okada T, Ohno A, Otani K, Sawayama R, Kawamura K, Okamoto M, Oshitani H.

Virus Genes. 2013 Sep 29. [Epub ahead of print]

10.

Oseltamivir-resistant influenza A(H1N1)pdm09 virus in southern Brazil.

Marx C, Gregianini TS, Lehmann FK, Lunge VR, Carli Sd, Dambrós BP, Tumioto GL, Seadi C, Fonseca AS, Ikuta N.

Mem Inst Oswaldo Cruz. 2013 May;108(3). pii: S0074-02762013000300392. doi: 10.1590/S0074-02762013000300021.

11.

The TLR4 antagonist Eritoran protects mice from lethal influenza infection.

Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini TL, Weiss J, Chen WH, Ernst RK, Rossignol DP, Gusovsky F, Blanco JC, Vogel SN.

Nature. 2013 May 23;497(7450):498-502. doi: 10.1038/nature12118. Epub 2013 May 1.

12.

Broadly neutralizing antibodies against influenza viruses.

Laursen NS, Wilson IA.

Antiviral Res. 2013 Jun;98(3):476-83. doi: 10.1016/j.antiviral.2013.03.021. Epub 2013 Apr 9. Review.

13.

Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets.

Pizzorno A, Abed Y, Rhéaume C, Bouhy X, Boivin G.

Antimicrob Agents Chemother. 2013 Apr;57(4):1784-9. doi: 10.1128/AAC.02269-12. Epub 2013 Jan 28.

14.

Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza.

Yates PJ, Mehta N, Horton J, Tisdale M.

Antimicrob Agents Chemother. 2013 Apr;57(4):1677-84. doi: 10.1128/AAC.02145-12. Epub 2013 Jan 18.

15.

Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.

Kaminski MM, Ohnemus A, Staeheli P, Rubbenstroth D.

J Virol. 2013 Feb;87(3):1912-5. doi: 10.1128/JVI.02507-12. Epub 2012 Nov 28.

16.

Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks.

Anekthananon T, Pukrittayakamee S, Ratanasuwan W, Jittamala P, Werarak P, Charunwatthana P, Suwanagool S, Lawpoolsri S, Stepniewska K, Sapchookul P, Puthavathana P, Fukuda C, Lindegardh N, Tarning J, White NJ, Day N, Taylor WR.

J Antimicrob Chemother. 2013 Mar;68(3):697-707. doi: 10.1093/jac/dks418. Epub 2012 Nov 9. Erratum in: J Antimicrob Chemother. 2013 Jul;68(7):1695. Pukritayakamee, S [corrected to Pukrittayakamee, S].

17.

Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: a molecular dynamics study.

Han N, Liu X, Mu Y.

PLoS One. 2012;7(9):e44057. doi: 10.1371/journal.pone.0044057. Epub 2012 Sep 6.

18.

I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y.

LeGoff J, Rousset D, Abou-Jaoudé G, Scemla A, Ribaud P, Mercier-Delarue S, Caro V, Enouf V, Simon F, Molina JM, van der Werf S.

PLoS One. 2012;7(8):e37095. doi: 10.1371/journal.pone.0037095. Epub 2012 Aug 24.

19.

High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery.

Patel DA, Patel AC, Nolan WC, Zhang Y, Holtzman MJ.

PLoS One. 2012;7(5):e36594. doi: 10.1371/journal.pone.0036594. Epub 2012 May 4.

20.

Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic.

Kumar S, Henrickson KJ.

Clin Microbiol Rev. 2012 Apr;25(2):344-61. doi: 10.1128/CMR.05016-11. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk